Skip to main content
. 2019 Apr 17;7(3):112–124. doi: 10.1002/iid3.249

Figure 4.

Figure 4

IL‐2 dampens GC‐mediated suppression of IL‐13. A, Th2 cells cultured with high IL‐2 (5 ng/mL) had significantly more IL‐13 mRNA compared to those cultured in low IL‐2 (1.25 ng/mL; n = 6). B, Genome browser tracks for STAT5 ChIP under control and IL‐2 replete conditions within the Th2 locus control region, an enhancer of IL‐13. C, Th2 cells cultured in high or low IL‐2 showed no difference in cell number (n = 6). D, The ability of DEX treatment to suppress IL‐13 mRNA was significantly less when Th2 cells were cultured in high IL‐2 vs low IL‐2 (n = 6). E, Continual exposure to DEX was required for suppression of IL‐13, since Th2 cells pretreated with DEX (24 hours) and then activated (ACT) with PMA/ionomycin (24 hours) in the absence of DEX (DEX/ACT) had significantly more IL‐13 mRNA than Th2 cells receiving DEX both as a pretreatment and during activation (DEX/ACT + DEX; n = 3). Data are presented as mean ± standard error. *P < 0.05 comparison of DEX vs vehicle for each IL‐2 concentration; # P < 0.05, comparison of each DEX concentration high vs low IL‐2. ChIP, chromatin immunoprecipitation; DEX, dexamethasone; IL‐2, interleukin 2; mRNA, messenger RNA; STAT5, signal transducer and activator of transcription 5; Th2, T‐helper cell